本次合作将Mirxes的突破性miRNA及多组学技术、核心产品(GASTROClear及LUNGClear)及其日益成熟 的临床管线(涵盖结直肠癌、肝癌、乳癌的成熟临床管线及CADENCE多癌种检测)与Apollo丰富的临床 专业知识、全国医院网络及社区医疗服务的提供能力结合，以实现宏伟的愿景：及早检测癌症、于可治 愈时介入及改变数百万患者的治疗结果。 本次合作旨在规模化地实现该等解决方案的商业化及市场采用，继而扩大区域内早期疾病筛检的覆盖范 围。董事会亦认为，与Apollo的建议战略合作属重大协同机会，符合本集团的长远战略目标。合作旨在 凭借Apollo的广大医院网络及庞大患者群，促进本集团癌症早期检测解决方案的广泛使用，继而弥补印 度医疗体系中的现存不足，尤其是在早期检测及疾病筛查方面。董事会进一步认为，是次合作可为本集 团未来在印度扩充业务的延展平台，有助更早进行临床干预，并改善患者的治疗效果。 MIRXES-B(02629)发布公告，本公司已与Apollo Health and Lifestyle Limited(AHLL，为Apollo Hospitals Enterprise Limited(Ap ...

本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 諒解備忘錄 本公司董事（「董事」）會（「董事會」）宣佈，本公司已與Apollo Health and Lifestyle Limited（「AHLL」，為Apollo Hospitals Enterprise Limited（「Apollo」）的全資附屬公 司）訂立諒解備忘錄（「諒解備忘錄」）以尋求進行戰略合作，從而於印度及鄰近 國家共同開發及商業化先進的癌症早期檢測解決方案。待達成協定目標及獲 各自董事會批准後，預期將會於印度創立一家合營公司，根據本公司及Apollo 將注入的知識產權、臨床管線、研發、臨床試驗基礎設施及商業渠道，其股權 價值將不少於50百萬美元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limite ...

Key Takeaways ACHC beat Q4 earnings and revenue estimates as admissions and patient days increased.ACHC's same-facility revenues rose 4.4% on 3.1% higher patient days and 2.5% admissions growth.ACHC sees 2026 revenues of $3.37B-$3.45B and adjusted EBITDA of $575M-$610M.Acadia Healthcare Company, Inc. (ACHC) reported adjusted fourth-quarter earnings of 7 cents per share, which beat the Zacks Consensus Estimate of 3 cents. However, the bottom line declined 89% year over year.Total revenues increased 6.1% year ...

CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -48.94%. A quarter ago, it was expected that this molecular diagnostics company would post earnings of $0.13 per share when it actually produced earnings of $0.28, delivering a surprise of +115.38%.Over the last four quarte ...

Management attributed overperformance in 2025 to strong execution across all segments and a successful first year of the 2025-2027 long-range plan.Strategic positioning was strengthened by securing a 25-year license renewal for the Ottawa facility, the longest ever issued by the Canadian Nuclear Safety Commission.Cross-business unit (XBU) initiatives gained momentum, with revenue from customers using multiple segments growing 9% year-over-year.Nelson Labs achieved significant margin expansion of 312 basis p ...

Nelson Labs: Q4 revenue increased 2.3% to $55 million (nearly flat constant currency). Pricing and core lab testing growth were partially offset by lower expert advisory services revenue. Segment income rose 1.9% to $18 million.Nordion: Q4 revenue declined 12.3% to $50 million due to harvest-schedule timing that drove 15% unfavorable volume and mix, partially offset by 2.4% favorable pricing. Segment income fell 18.9% to $29 million, with margin down 466 basis points to 57.5%.Sterigenics: Q4 revenue grew 10 ...

Sotera Health Company (NasdaqGS:SHC) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDavid Windley - Managing Director and Founding Member of Healthcare Equity Research TeamJason Peterson - VP of Investor Relations and TreasuryJonathan M. Lyons - CFOMichael Petras - Chairman and CEOSam Eiber - Equity Research AssociateConference Call ParticipantsBrett Fishman - VP and Senior Equity Research AnalystCasey Woodring - VP and Senior Equity Research AnalystChristine Rains - Healthcare Equi ...

Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [5][15] - Adjusted EBITDA rose by 8.2% to $593.8 million, or 7.8% on a constant currency basis, with margins expanding to 51%, an increase of 118 basis points [5][15] - Adjusted EPS for the year was $0.86, an increase of $0.16 versus 2024, driven by operational growth and a lower tax rate [16] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, or 8% on a constant currency basis, driven by favorable pricing and volume [12] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest timing [13] - Nelson Labs revenue increased by 2.3% to $55 million, with favorable pricing and core lab testing growth partially offset by lower advisory services revenue [14] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [6] - Revenue from XBU customers expanded by 9% year-over-year, reflecting successful cross-selling initiatives [6][50] Company Strategy and Development Direction - The company aims to execute its 2025-2027 long-range plan, focusing on operational excellence, disciplined capital deployment, and enhancing free cash flow [8][21] - The construction of a new X-ray facility is planned to open in 2026, which is part of a strategic investment to expand service offerings [6][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, emphasizing strong cash flow generation and customer relationships [21][105] - The company expects total revenue for 2026 to be in the range of $1.233 billion to $1.251 billion, representing 5%-6.5% constant currency growth [9][18] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [7] - The company has approximately $940 million of available liquidity as of December 31, 2025 [16] Q&A Session Summary Question: Guidance and EBITDA margins - Management indicated that the expected EBITDA margin expansion is primarily due to normal operating leverage without any unusual dynamics [23][24] Question: Sterigenics client insourcing - Management noted that while one client is transitioning back to outsourcing, significant shifts in the market are not yet observed due to extended compliance periods [25][26] Question: 2026 outlook for Sterigenics - Management expects mid to high single-digit constant currency revenue growth for Sterigenics in 2026, with a soft start anticipated in Q1 [18][32] Question: Nelson Labs margins - Management expects Nelson Labs to maintain margins in the low to mid 30% range, with Q1 typically being the softest quarter [34][35] Question: Nordion segment headwinds - Management clarified that Nordion's challenges were due to Cobalt-60 harvest timing rather than demand issues [84][85] Question: Competitive positioning in Sterigenics - Management believes Sterigenics is well-positioned despite the extended compliance period, with strong customer satisfaction scores [68][69] Question: Impact of onshoring - Management has not seen significant movement towards onshoring but is prepared for potential shifts in the market [87] Question: Volume and mix visibility - Management indicated that volume and mix are key factors that could drive performance towards the higher end of guidance [91][92]

Sotera Health Company (NasdaqGS:SHC) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Speaker9Please note this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations, Jason Peterson. Jason, please go ahead.Speaker5Good morning. Thank you. Welcome to Sotera Health's fourth quarter and full year 2025 earnings call. Today's press release and supplemental slides are available on the investor section of our website at soterahealth.com. This webcast is bei ...

Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +7.22%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.26, delivering a surprise of +18.18%.Over the last four quarters, the co ...